Guardant Health (GH) Cost of Revenue (2024 - 2026)

Guardant Health has reported Cost of Revenue for 3 years, with the latest figure at $115.9 million in Q2 2026.

• Quarterly Cost of Revenue rose 42.79% year-over-year to $115.9 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $413.9 million (up 34.39% YoY) and the FY2025 annual result came in at $349.0 million, up 20.43% from the prior year.
• Cost of Revenue rose to $115.9 million in Q2 2026 per GH's latest filing, from $104.9 million in the prior quarter.
• Over five years, Cost of Revenue peaked at $115.9 million in Q2 2026 and troughed at $65.3 million in Q1 2024.
• A 3-year average of $86.0 million and a median of $79.4 million in 2024 frame the typical range for Cost of Revenue.
• The sharpest annual moves came in 2025 and 2026: Cost of Revenue rose 12.13% in 2025, then jumped 42.79% in 2026.
• Over 3 years, Cost of Revenue stood at $77.6 million in 2024, then climbed by 28.22% to $99.5 million in 2025, then grew by 16.54% to $115.9 million in 2026.
• According to Business Quant data, Cost of Revenue over the past three periods registered $115.9 million, $104.9 million, and $99.5 million for Q2 2026, Q1 2026, and Q4 2025 respectively.